Business
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026; continued enrollment in breast cancer triplet combinations -- Next-generation PI3Kα pan-mutant inhibitor development candidate for HR+ metastatic breast cancer is expected to be announced in March 2026 -- Approximately $59M in cash and cash equivalents at the end of Q4 2025 BOULDER, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focu
About this update from Onkure Therapeutics, Inc.
[{"type":"image","alt":"OnKure Therapeutics, Inc.","displaySize":"","headline":null,"caption":"OnKure Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/80a75f50988a3e7732dc404944bce001"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lmQIfegLNApEkytHgGTsoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/80a75f50988a3e7732dc404944bce001","width":300,"height":150}},"lazy":false},{"type":"text","content":"-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026; continued enrollment in breast cancer triplet combinations ","length":144,"tagName":"p"},{"type":"text","content":"-- Next-generation PI3Kα pan-mutant inhibitor development candidate for HR+ metastatic breast cancer is expected to be announced in March 2026","length":142,"tagName":"p"},{"type":"text","content":"-- Approximately $59M in cash and cash equivalents at the end of Q4 2025","length":72,"tagName":"p"},{"type":"text","content":"BOULDER, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided recent business highlights.","length":320,"tagName":"p"},{"type":"text","content":"“We are pleased with the continued progress across our PI3Kα‑focused pipeline, including the steady execution of the PIKture‑01 trial of OKI-219. We look forward to sharing updated data from this trial later this month,” said Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure. “We are also excited to announce our next‑generation pan‑mutant inhibitor development candidate for HR+ metastatic breast cancer this month and provide additional information on our program in vascular malformations later this year. Overall, we believe our progress to date underscores the power of our mutation‑selective approach to PI3Kα inhibition and reinforces the momentum we are building as we work to deliver scientifically differentiated therapies to patients.”","length":772,"tagName":"p"},{"type":"text","content":"OKI-219 Program Highlights","length":26,"tagName":"p"},{"type":"text","content":"OnKure’s lead prod...